Researchers have developed a computational method that considers uncommon CYP2D6 variants to assess patient-specific metabolism of tamoxifen and other drugs.
Biotheranostics' Breast Cancer Index Included in Latest NCCN Guidelines
The expert body now recognizes the test's ability to predict whether early-stage breast cancer patients will benefit from extended, adjuvant endocrine therapy.
OncotypeDX Score May Give Valuable Info on Breast Cancer Locoregional Recurrence
Such prognostic information could aid clinicians in making decisions about radiotherapy for postmenopausal women with breast cancer.
Data shows CYP2D6 testing in breast tumor tissue can be inaccurate due to loss of heterozygosity, and may have obscured the connection between genotype and tamoxifen response in previous trials.